These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27592718)

  • 1. From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine.
    Pichardo-Almarza C; Diaz-Zuccarini V
    Curr Pharm Des; 2016; 22(46):6903-6910. PubMed ID: 27592718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
    Fleisher B; Brown AN; Ait-Oudhia S
    Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
    Bárczi G; Merkely B
    Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    Alkhalil M; Choudhury RP
    JAMA; 2017 Apr; 317(16):1690-1691. PubMed ID: 28444271
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    Murray SW
    JAMA; 2017 Apr; 317(16):1690. PubMed ID: 28444270
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials.
    van de Steeg E; Kleemann R; Jansen HT; van Duyvenvoorde W; Offerman EH; Wortelboer HM; Degroot J
    J Pharmacol Exp Ther; 2013 Dec; 347(3):635-44. PubMed ID: 24049060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Effect of Statins and Patient Adherence in Atherosclerosis via a Quantitative Systems Pharmacology Model Using a Novel, Hybrid, and Multi-Scale Approach.
    Pichardo-Almarza C; Diaz-Zuccarini V
    Front Pharmacol; 2017; 8():635. PubMed ID: 28955237
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational therapies for the treatment of atherosclerosis.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].
    Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hartung HP
    Nervenarzt; 2003 Aug; 74(8):704-7. PubMed ID: 12904873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plant sterols and their role in combined use with statins for lipid lowering.
    Normén L; Holmes D; Frohlich J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):307-16. PubMed ID: 15816508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New American College of Cardiology and American Heart Association cholesterol treatment guidelines: subjects with Type 2 diabetes are under treated with high-intensity statins.
    Tripolt NJ; Sourij H
    Diabet Med; 2014 Jul; 31(7):879-80. PubMed ID: 24612178
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 16. Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model.
    Uatay A; Gall L; Irons L; Tewari SG; Zhu XS; Gibbs M; Kimko H
    J Pharm Sci; 2024 Jan; 113(1):11-21. PubMed ID: 37898164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin therapy in ARAS: beyond cholesterol lowering.
    Meier P
    Am J Hypertens; 2008 Oct; 21(10):1075. PubMed ID: 18806771
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease.
    de Lau LM; Stricker BH; Breteler MM
    Mov Disord; 2007 Oct; 22(13):1985. PubMed ID: 17557354
    [No Abstract]   [Full Text] [Related]  

  • 19. [Role of rosuvastatin in current lipid-lowering therapy].
    Abel T; Fehér J
    Orv Hetil; 2010 Aug; 151(35):1424-8. PubMed ID: 20719717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008.
    Lewis SJ
    Am J Med; 2009 Jan; 122(1 Suppl):S38-50. PubMed ID: 19110087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.